Sanofi Annual Report 2022, page-17

Our relationship with AZ isn’t terminated. We do know they are very interested in our dendrimers of course. Along with all the other partners that we’ve developed molecules for them to play with. It’s just a waiting game imo. All be it a long one. A solid deal could come from any one of them particularly once proof of concept for our in-house trials, in total, are revealed, which could see AZ pick them up. I’ve just accepted that missing timelines is expected. There are variables that are out of managements control. People die or are unable to continue trials for various reasons. Big competition for recruitment exists, no doubt big pharma afford priority. Covid hasn’t gone away still causes delays no doubt. This sort of thing has been communicated to shareholders.